Low-grade inflammation is a hallmark of adipose tissue expansion in obesity, which is associated with an accumulation of macrophages and cytokines in the tissue ([@B1]). Furthermore, low-grade inflammation may play a causal role in the link between obesity and systemic insulin resistance. Cytokines produced and present in adipose tissue are often referred to as adipokines and include leptin, resistin, IL6, osteopontin (OPN), etc. OPN is one of the most abundant cytokines in adipose tissue of obese individuals ([@B2],[@B3]), and expression of *OPN* showed large differences in adipose tissue between monozygotic twins discordant for obesity ([@B3]). OPN is a secreted glycoprotein containing an Arg-Gly-Asp-Ser sequence that can interact with integrins and CD44 receptors and recruit macrophages and T cells to inflammatory sites ([@B4]). Whereas mice fed a high-fat diet became obese and displayed increased circulating OPN concentrations, obese mice lacking OPN showed increased insulin sensitivity ([@B2]), thereby proposing OPN as a key player in high-fat diet--induced insulin resistance. Besides an effect on insulin, the incretin hormone glucose-dependent insulinotropic polypeptide (GIP) exerts strong effects on adipose tissue formation. GIP stimulates adipose tissue formation independently of its effect on insulin secretion ([@B5]), and inactivation of the GIP receptor (GIPR) in adipose tissue has been suggested as a strategy to treat obesity ([@B6]).

We have previously demonstrated that GIP stimulates expression of OPN in human islets where OPN exerts protection against cytokine-induced apoptosis ([@B7]). Also, a variant in the *GIPR* locus (single nucleotide polymorphism \[SNP\] rs10423928) was associated with impaired insulin secretion and decreased BMI, which was sufficient to ameliorate the risk of type 2 diabetes associated with impaired insulin secretion. Given the putative important role of GIP in adipose tissue biology as well as a suspected role of OPN in adipose tissue subclinical inflammation, we hypothesized that GIP may also stimulate the expression of OPN in adipose tissue and thereby induce insulin resistance. The aim of this study was thus to explore whether GIP effects on adipose tissue may also include stimulation of OPN and induction of insulin resistance, and whether this was influenced by a variant in the *GIPR* gene.

RESEARCH DESIGN AND METHODS {#s1}
===========================

All human and animal protocols were approved by the local ethics committees and performed in accordance with local institutional and national regulations.

Study participants {#s2}
------------------

### Prevalence, Prediction, and Prevention of Diabetes. {#s3}

The PPP-Botnia Study (Prevalence, Prediction, and Prevention of Diabetes) is a population-based study from the Botnia region, which included ∼7% of the population 18--75 years of age (mean age 51 ± 17 years) ([@B8]). The aim was to study the prevalence and presence of risk factors for diabetes, impaired glucose tolerance, and metabolic syndrome in the general population. Diagnosis of diabetes was confirmed from subject records or on the basis of a fasting plasma glucose concentration ≥7.0 mmol/L and/or 2-h glucose ≥11.1 mmol/L. Nondiabetic subjects (*n* = 4,532) were included in the current study.

### Measurements. {#s4}

In the PPP-Botnia Study, blood samples were drawn at 0, 30, and 120 min of the oral glucose tolerance test (OGTT). Levels of human GIP (total) and OPN in plasma were assayed using the Quantikine GIP and OPN ELISA kit (Millipore; R&D Systems, Abingdon, U.K.) according to the manufacturer's instructions. Absorbance was measured at 450 nm and the lower limit of detection was 5.7 pg/mL.

### Calculations. {#s5}

Insulin sensitivity index (ISI) from the OGTT was calculated as 10,000/√(fasting plasma glucose \[mg/dL\] × fasting insulin \[µU/L\] × mean OGTT~glucose~ × mean OGTT~insulin~) ([@B9]).

Subcutaneous and visceral fat from individuals undergoing bariatric surgery. {#s6}
----------------------------------------------------------------------------

Abdominal visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) biopsies were available from 38 obese nondiabetic subjects undergoing bariatric surgery at Landskrona Hospital (Landskrona, Sweden) (5 men and 33 women; 36 (30--47) years of age; weight = 112 (102--124) kg; BMI = 41 ± 5 kg/m^2^; total body fat mass = 68 ± 14 kg). Biopsies were immediately frozen in liquid nitrogen and stored at −80°C.

### Danish Twins Study. {#s7}

Of 606 mono- and dizygotic same-sex twins previously participating in a population-based study ([@B10],[@B11]), 298 elderly twins (mean age 74 ± 5 years) were examined with a standardized OGTT and anthropometric measurements. In this cohort, 57% were normal glucose tolerant, 27% had impaired glucose tolerance, and 16% had type 2 diabetes.

### Measurements. {#s8}

In addition to an OGTT, a SAT biopsy was taken from the abdomen under local anesthesia using a Bergstrom needle, and the tissue was immediately frozen in liquid nitrogen and stored at −80°C.

### Danish overfeeding study. {#s9}

Forty-eight young male volunteers born in 1979--1980 in Copenhagen were recruited from the Danish National Birth Registry ([@B12]). None of the participants had known illness or took medications known to affect the study outcome.

### Indirect calorimetry. {#s10}

Basal and insulin-stimulated glucose and fat oxidation rates were calculated as GOX (g/min) = 4.55 × VCO~2~ (L/min) − 3.21 × VO~2~ (L/min) − 2.87 × n (g/min) and FOX = 1.67 × VO~2~ (L/min) − 1.67 × VCO~2~ (L/min) − 1.92 × n (g/min), where n is nitrogen secreted in the urine ([@B13]). Glucose and lipid oxidation are expressed as mg ⋅ kg FFM^−1^ ⋅ min^−1^.

### EUGENE2 Study. {#s11}

The participants included in this study were 110 healthy, nondiabetic offspring of patients with type 2 diabetes from the Kuopio center of the EUGENE2 Study ([@B14]). One of the parents had to have type 2 diabetes and the other parent normal glucose tolerance in an OGTT and/or no history of type 2 diabetes in the family. All these subjects (36.6 ± 6.0 years of age; BMI 25.9 ± 4.7 kg/m^2^) underwent an adipose tissue needle biopsy from abdominal subcutaneous tissue as previously reported ([@B15]). All protocols were approved by the regional ethics committee, and procedures were performed according to the principles of the Helsinki Declaration. After thorough written and oral explanation of the study, all subjects gave their written consent.

Measurements of *GIPR* and *OPN* mRNA expression. {#s12}
-------------------------------------------------

mRNA levels were measured in adipose tissue (subcutaneous and visceral fat from Landskrona obese) by real-time quantitative RT-PCR (TaqMan Gene Expression Assays; Applied Biosystems) according to the manufacturer's protocols. RNA was isolated using the RNeasy Plus Minikit (Qiagen, Valencia, CA). Concentration and purity were measured using NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE). No sign of degradation was observed using agarose gel electrophoresis and Experion DNA 1-K gel chips (Bio-Rad, Hercules, CA). RNA (0.2--0.5 μg) was used for cDNA synthesis with RevertAid First Strand cDNA Synthesis Kit (Fermentas Life Sciences). TaqMan gene expression assays were purchased from Applied Biosystems. For human tissue, assay IDs were Hs00164732_m1 for GIPR and Hs00959010_m1 for OPN (SPP1). Target gene expression was normalized to the expression of the following housekeeping genes: human *HPRT1* (HGPRT, article no. 4326321E), human *PPIA* (cyclophilin A, article no. 4326316E), human *POLR2A* (POLR2A, article Hs00172187_m1). Q-PCR reactions were run on ABI 7900 HT (Applied Biosystems) using 5--10 ng cDNA, and all assays were run in triplicate (total volume of PCR reactions = 10 µL). Relative quantity of *GIPR* and *OPN* mRNA was calculated using the comparative threshold method, and normalization was performed using Genorm version 3.5 software.

Western blotting. {#s13}
-----------------

Primary adipocytes were isolated from the epididymal fat pads of 36--42-day-old male Sprague-Dawley rats by collagenase digestion as previously described ([@B16]). Primary rat adipocytes (10% cell suspension) were suspended in serum-free Dulbecco's modified Eagle's medium supplemented with 0.5% BSA, 100 units/mL penicillin, and 100 μg/mL streptomycin. Adipocytes were transferred to six-well plates (1-mL cell suspension per well) and incubated at 37°C with 95% O~2~/5% CO~2~ for 2 h prior to addition of 100 nmol/L GIP or 1 nmol/L insulin alone or in combination. After an overnight (∼18 h) incubation with the hormones, cells were washed with Krebs-Ringer-HEPES buffer containing 25 mmol/L HEPES, 200 nmol/L adenosine, and 2 mmol/L glucose prior to lysis in a buffer containing 50 mmol/L N-\[tris(hydroxymethyl)methyl\]-2-aminoethanesulfonic acid (TES), 2 mmol/L EGTA, 1 mmol/L EDTA, 250 mmol/L sucrose, 40 mmol/L phenylphosphate, 5 mmol/L NaF, 1 mmol/L dithioerythriol, 0.5 mmol/L sodium orthovanadate, 10 μg/mL antipain, 10 μg/mL leupeptin, 1 μg/mL pepstatin A, and 1% Nonidet P40. Protein was determined by Bradford assay. Aliquots of the cell lysates (20 μg) were mixed with Laemmli sample buffer, separated on 12% polyacrylamide gels, and subsequently transferred to nitrocellulose membranes (Amersham Biosciences, Buckinghamshire, U.K.). After blocking in 3% BSA/5% nonfat dry milk, membranes were incubated with primary antibody against OPN (1 μg/mL; Developmental Studies Hybridoma Bank, Iowa City, IA) and horseradish peroxidase (HRP)-conjugated secondary antibody (Amersham Biosciences), and bands were detected with Supersignal West Pico ECL reagents (Pierce Biotechnology, Rockford, IL). Western blots were quantified using Image Gauge software (Fujifilm).

Splicing analysis {#s14}
-----------------

### Subjects and RNA extraction. {#s15}

A total of 110 nondiabetic offspring of type 2 diabetic patients (36.6 ± 6.0 years of age, BMI = 25.9 ± 4.7 kg/m^2^) from the Kuopio center of the EUGENE2 Study ([@B14]) underwent an adipose needle biopsy from abdominal subcutaneous tissue. Total RNA from biopsies was isolated using Trizol reagent (Invitrogen, Carlsbad, CA) and Qiagen RNeasy Minikit (Ambion, Austin, TX) and transcribed to cDNA using random primers and a high-capacity cDNA archive kit (Applied Biosystems). Quantitative RT-PCRs were performed in a 7,500 Real-Time PCR System (Applied Biosystems) using 6 ng (RNA equivalents) cDNA as template, gene-specific primers, and probes (information on primers and probes available upon request from Applied Biosystems). Target gene expression was normalized to large ribosomal protein P0 (Hs99999902_ml; Applied Biosystems) using the standard curve method.

### Identification of GIPR splice variants. {#s16}

Analytical RT-PCRs were performed on cDNA from visceral fat and subcutaneous fat in 15-μL reactions using 7.5 μL AmpliTaq Gold PCR Master Mix (Applied Biosystems, Foster City, CA) supplemented with 0.75 μL DMSO and 1.5 µmol/L forward and reverse primer. The following primers were used in various combinations: exon1fw, GGCTGCAGGAGCAAGTGA; exon2fw, GATCGCCCCTGCACGAAC; exon5fw, TTGGAGAGACCATACACAATGTG; exon8fw, CTGCCTGCCGCACGGCCCAGAT; exon10fw, GGATTATACGGACCCCCATC; exon5rv, CACATTGTGTATGGTCTCTCCAA; exon8rv, GTTGGCACCCACGCAGTA; exon10rv, CAAATGGCCTTGACTTCGTTG; exon11rv, CGTGTCCTCAGCTTGGACA; and exon14rv, CGCCCCTAGCAGTAACTTTCC. The reactions were carried out with 60°C annealing temperature and \>50 cycles. Products were analyzed on 2% agarose. Prior to sequencing, 2.5 µL PCR product was treated with 0.5 µL ExoSAP-IT (USB, Cleveland, OH) at 37°C for 30 min and deactivated at 80°C for 15 min. Subsequently, 1 μL was sequenced in both directions using BigDye 3.1 according to the manufacturer's protocol (Applied Biosystems, Foster City, CA). The sequence reactions were purified and analyzed by RSKC (Malmö, Sweden).

### Quantitative analysis of alternative splicing between exons 8 and 10. {#s17}

For PCR reactions, 5 ng cDNA was added to PCR reaction mixture consisting of onefold PCR buffer, 200 μmol/L dNTPs, 150 μmol/L forward and reverse primers, and 0.4 units DyNAzyme II Hot Start DNA Polymerase (Finnzymes, Espoo, Finland). Primers were planned to span an alternatively spliced region resulting in PCR products that vary in size depending on splicing. For DNA fragment analysis, PCR products were diluted to avoid saturation of capillary electrophoresis (1:4 in water). One microliter of PCR product dilution was mixed with 10 µL HiDi formamide (ABI) and 0.4 µL of internal size standard GeneScan 600 LIZ (ABI; Applied Biosystems). Samples were denatured for 5 min at 95°C and then immediately placed on ice for at least 15 min. Samples were run on the ABI3100 DNA Genetic Analyzer (ABI), and the results were analyzed using Peak Scanner Software version 1.0 (ABI). Peak areas were used to calculate the relative quantities of the PCR products.

Detection of GIPR protein by immunohistochemistry {#s18}
-------------------------------------------------

### Human tissue. {#s19}

White adipose tissue (*n* = 20) was taken during obesity surgery from healthy volunteers. Adipose and skeletal muscle specimens were immediately fixed in 4% paraformaldehyde in 0.1 mol/L phosphate buffer (pH 7.2) at 4°C, rinsed in graded ethanols, embedded in paraffin, and sectioned (6 μm).

### Animal tissue. {#s20}

For adipose and skeletal tissue, Sprague Dawley rats (*n* = 10) and C57Bl/6J mice (*n* = 10; Taconic Europe, Ry, Denmark) were used. Specimens were dissected out, fixed overnight in Stefanini's solution (2% paraformaldehyde and 0.2% picric acid in 0.1 mol/L PBS, pH 7.2), rinsed thoroughly in Tyrode's solution containing 10% sucrose, embedded, and cryosectioned (10 μm). Cell membranes were stained with CellMask (Invitrogen).

### Immunofluorescence. {#s21}

Adipose and muscle tissue were stained as previously described ([@B15]). In brief, sections were boiled in 0.01 mol/L citrate buffer (pH 6.0) for 2 × 7 min at 650 W. Primary antibodies were diluted in PBS containing 0.25% BSA and 0.25% Triton X-100 and applied overnight at 4°C. Rabbit polyclonal anti-GIPr (1:1,600) ([@B7],[@B17]) was used. Secondary antibodies specific for rabbit IgG and coupled to Cy2 (Jackson, West Grove, PA) were applied for 1 h at room temperature. Immunofluorescence was examined in an epifluorescence microscope (Olympus BX60). Images were taken with a digital camera (Nikon DS-2Mv).

Genotyping. {#s22}
-----------

Genotyping of rs10423928 was performed using matrix-assisted laser desorption ionization time of flight mass spectrometry on the Sequenom MassARRAY platform (San Diego, CA) for PPP-Botnia and using an allelic discrimination method with a TaqMan assay on the ABI 7900 platform (Applied Biosystems, Foster City, CA) for the Danish Twins Study and EUGENE2. We obtained an average genotyping success rate of \>95.5% and an average concordance rate in all studies of \>99.9%. Hardy-Weinberg equilibrium was fulfilled in all studied populations (*P* \> 0.50).

Statistical analyses. {#s23}
---------------------

Linear regression analyses were used to test genotype-phenotype correlations adjusted for age, sex, and BMI (apart from BMI). Nonnormally distributed variables were logarithmically (natural) transformed before analysis. Analyses were performed using SPSS version 17.0, PLINK, or STATA version 10. For in vitro studies, results were expressed as mean ± SEM, where applicable. Statistical analyses were performed using GraphPad (Prism 4.0) or Origin (Originlab), and significance was determined using unpaired two-tailed Student *t* test. *P* value \<0.01 was considered statistically significant unless replicating previous findings, when the threshold was set at *P* \< 0.05.

RESULTS {#s24}
=======

GIPR expression in adipose tissue. {#s25}
----------------------------------

Expression of GIPR determined both by real-time PCR and immunostaining demonstrated that the GIPR protein was abundant in adipose tissue and skeletal muscle ([Fig. 1*A*](#F1){ref-type="fig"} and [Supplementary Fig. 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db12-0976/-/DC1)). Expression of *GIPR* mRNA was higher in visceral than in subcutaneous fat (mean ± SEM, 0.45 ± 0.04 vs. 0.28 ± 0.03, *P* = 2.0 × 10^−6^) in 30 obese nondiabetic subjects undergoing bariatric surgery. Circulating fasting plasma GIP concentrations were positively associated with BMI, and to a lesser extent with lean body mass (LBM) and fat (%) (BMI, *r* = 0.054, *P* = 0.0003; fat %, *r* = 0.038, *P* = 0.045; LBM, *r* = 0.043, *P* = 0.023), but negatively associated with insulin sensitivity (ISI) (*r* = −0.096, *P* = 3.8 × 10^−10^) in nondiabetic participants from the PPP-Botnia Study ([Supplementary Table 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db12-0976/-/DC1)) ([@B7]). Of note, the number of individuals with measurements of LBM and fat percentage were fewer than those with information on BMI (2,826 vs. 4,468). On the contrary to plasma GIP concentrations, increased *GIPR* mRNA levels correlated negatively with BMI and waist circumference in the EUGENE2 and Danish Twins studies, as well as with visceral fat mass (*r* = −0.53, *P* = 1 × 10^−6^), but not with subcutaneous fat (*r* = −0.11, *P* = 0.26) measured by computed tomography in the EUGENE2 cohort ([Supplementary Table 2](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db12-0976/-/DC1)). There was a weak inverse relationship between fasting plasma GIP concentrations and *GIPR* mRNA in adipose tissue (*n* = 197, *r* = −0.155, *P* = 0.030), especially in hyperglycemic (impaired fasting glucose and T2D) individuals (*n* = 75, *r* = −0.342, *P* = 0.003). This could be a corollary of the larger variation in GIP concentrations seen in hyperglycemic individuals.

![Expression of the GIPR in adipose tissue. *A*: Immunostainings demonstrating that GIPR (green) is abundantly expressed in human, mouse, and rat white adipose tissue (*top*) and skeletal muscle (*bottom*). Scale bar, 50 µm. *B*: Agarose gel electrophoresis of RT-PCR across the variable part of GIPR cDNA (from exon 2 to 10) from SAT and VAT samples from seven individuals. The size of the predicted functional GIPR amplicon of 887 bp is indicated, as well as the size range of identified splice variants (green bars). *C*: Schematic representation of alternative splicing of the full-length GIPR. Black exons are obligatory and colored are variable. Dashed lines indicate rare events. Exon 1, which is noncoding, is presumably variable. Exons 3 and 5 possess alternative splice sites. The GIP binding site (HormR) and the transmembrane domain (7tm_2) are indicated. Transmembrane helices (gray) I, II, III, and VI are encoded by single exons. Splice variants were detected by RT-PCR and sequencing. Variants predicted to yield a fully functional membrane-bound GIPR are indicated by asterisks. *D*: Proportion of full mRNA splice variants including exon 9 is decreased in the adipose tissue of subjects with the A allele of rs10423928 (ANOVA, *P* \< 0.05). PCR primers are shown in exons 8 and 11. Variant ratios were detected using PCR and capillary electrophoresis. Peak areas were used to calculate the relative quantities of the PCR products.](2088fig1){#F1}

Of twin pairs discordant for BMI (difference of \>2 kg/m^2^), the twin with lower BMI showed higher expression of *GIPR* in subcutaneous fat (0.243 ± 0.02 vs. 0.147 ± 0.01, *P* = 0.001) than the obese twin. Consequently, increased *GIPR* mRNA in adipose tissue correlated positively with insulin sensitivity assessed as rates of whole-body glucose uptake (*r* = 0.39, *P* = 3 × 10^−5^) and glucose oxidation (*r* = 0.38, *P* = 7 × 10^−5^) measured during a hyperinsulinemic-euglycemic clamp as well as with adiponectin concentrations (*r* = 0.43, *P* = 2 × 10^−5^) ([Supplementary Table 2](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db12-0976/-/DC1)).

Effects of a variant in the *GIPR* gene (rs10423928) on body composition and metabolism. {#s26}
----------------------------------------------------------------------------------------

The A allele of a variant in the *GIPR* gene (rs10423928) was associated with lower BMI, fat, and LBM measured by bioimpedance ([@B7]), suggesting that the A allele is associated with reduced receptor function. The effect on LBM was replicated in 118 men measured by dual-energy X-ray absorptiometry showing that carriers of the A allele had a significant reduction in LBM of 2.88 kg (TT genotypes, 59.84 ± 6.53, vs. TA/AA genotypes, 56.95 ± 5.70 kg; *P* = 0.006) ([Supplementary Table 3](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db12-0976/-/DC1)). The association of the A allele with reduced fat mass was also supported by a decrease in serum leptin levels in men from the Botnia study (*n* = 484, β \[ln transformed\] ± SEM, −0.039 ± 0.02; mean ± TT, 5.22 ± 0.24, TA 4.80 ± 0.22, AA 3.79 ± 0.34 µg/L, *P* = 0.012).

In an overfeeding study ([@B12],[@B13]), GIP levels were significantly increased in homozygous TT carriers of *GIPR* rs10423928 (mean ± SD, 47.0 ± 17.1 vs. 90.7 ± 63.3 pg/mL; *P* = 0.003), but not in A-allele carriers (54.0 ± 22.5 vs. 65.7 ± 28.0 pg/mL; *P* = 0.12) ([Supplementary Table 4](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db12-0976/-/DC1)). In 48 young healthy men, the *GIPR* SNP rs10423928 was associated with changes in substrate oxidation during high-fat feeding. In hyperinsulinemic-euglycemic clamp and indirect calorimetry, carriers of the insulin-reducing A allele showed a slightly lower rate of fat oxidation (TT, 1.15 ± 0.44, vs. TA/AA, 0.84 ± 0.40 mg/kg FFM/min; *P* = 0.027) and higher rate of glucose oxidation (TT, 1.98 ± 0.64, vs. TA/AA, 2.55 ± 0.97 mg/kg FFM/min; *P* = 0.018), suggesting a change in the availability of fatty acid substrates to the mitochondria and a subsequent increase in glucose utilization ([Supplementary Table 4](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db12-0976/-/DC1)).

Although there was no eQTL (expression quantitative trait loci) effect of the *GIPR* rs10423928 genotype on total *GIPR* mRNA in SAT from 329 individuals ([Supplementary Table 5*A* and *B*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db12-0976/-/DC1)), we cannot exclude the possibility that the variant would influence expression of *GIPR* in a given individual in an allele-specific manner or its splicing pattern. A wide range of splice variants of *GIPR* was detected in SAT and VAT, of which only a few corresponded to the full-length (active) isoform ([Fig. 1*B*](#F1){ref-type="fig"}). To investigate this further, we used a nonsynonymous coding SNP (rs1800437) in strong linkage disequilibrium with rs10423928 as a reporter SNP for quantitative allele-specific expression analysis in adipose tissue (SAT and VAT from 20 individuals). It is unlikely that the SNP would influence the total amount of *GIPR* mRNA in an allele-specific manner as there was at most a 10% difference in expression of the C and G alleles in heterozygous (G/C) carriers of the *GIPR* rs1800437 ([Supplementary Fig. 2](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db12-0976/-/DC1)).

We next explored whether the rs10423928 SNP in the *GIPR* gene could influence the splicing pattern of *GIPR* in adipose tissue given that in mouse, there is clear evidence of alternative splicing of *GIPR* ([@B18]). Up to 64 possible variants were detected by RT-PCR and sequencing. Only two of these comprise the exons and splice sites predicted to yield a fully functional, membrane-bound GIPR, containing the intact NH~2~-terminal hormone-binding domain as well as the complete seven-helix membrane-spanning domain ([Fig. 1*C*](#F1){ref-type="fig"}). In adipose tissue from subjects with the A allele of SNP rs10423928 in the *GIPR* gene, a slight decrease in the proportion of splice variants containing exon 9, which is required for coding the transmembrane domain, was observed ([Fig. 1*D*](#F1){ref-type="fig"}).

GIP stimulates OPN in adipose tissue. {#s27}
-------------------------------------

OPN has been shown to be markedly increased in adipose tissue from obese individuals and has been suggested to link obesity with systemic insulin resistance ([@B2],[@B3]). In line with this, we observed that *OPN* expression was increased in adipose tissue from obese twins compared with their lean counterparts (mean ± SEM; *n* = 86, 0.13 ± 0.04 vs. 0.04 ± 0.01, *P* \< 0.05). *OPN* mRNA correlated positively with BMI (*n* = 196, *r* = 0.36, *P* = 3.1 × 10^−7^) and negatively with insulin sensitivity (*n* = 192, *r* = −0.24, *P* = 0.0008), but the inverse correlation between *OPN* mRNA and insulin sensitivity was restricted to carriers of the A allele (*n* = 39, TA/AA, *r* = −0.481, *P* = 0.002 vs. *n* = 44, TT, *r* = −0.056, *P* = 0.71) ([Fig. 2*A*](#F2){ref-type="fig"}). Carriers of the *GIPR* SNP rs10423928 TA/AA genotype had lower *OPN* expression in adipose tissue than TT genotype carriers (*P* \< 0.05) ([Fig. 2*B*](#F2){ref-type="fig"} and [Supplementary Table 5*A*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db12-0976/-/DC1)).

![Effects of GIP and *GIPR* genotype on OPN expression in adipocytes. *A*: Correlation between *OPN* mRNA in adipose tissue and ISI in different *GIPR* SNP rs10423928 carriers (Danish Twins Study, *n* = 83) (TT, black solid lines and gray circles; TA/AA, dashed lines and empty circles). *B*: Expression of *OPN* mRNA was lower in adipose tissue from TA/AA vs. TT genotype carriers (Danish Twins Study, *\*P* \< 0.05). *C*: GIP stimulation induces OPN in primary rat adipocytes. Adipocytes were isolated from rat epididymal fat pads and incubated overnight (∼18 h) in media containing either 5 or 25 mmol/L glucose in the presence of GIP and insulin at the indicated concentrations. Data are presented as mean ± SEM of OPN protein expression relative to β-actin, expressed as percent of control cell (25 mmol/L glucose) expression. *n* = 6--12 per condition. \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001.](2088fig2){#F2}

Notably, GIP stimulated OPN in isolated rat adipocytes incubated at high glucose in an insulin-dependent fashion (*P* \< 0.001) ([Fig. 2*C*](#F2){ref-type="fig"}).

DISCUSSION {#s28}
==========

The current study provides several novel insights into the role of GIP in the pathophysiology of obesity and type 2 diabetes by exploring a possible link between GIP, OPN, and insulin resistance. First, we confirm that increased OPN expression in human adipose tissue is associated with insulin resistance and obesity. Second, we present evidence that GIP stimulates OPN expression together with insulin in adipocytes, thereby contributing to adipose tissue inflammation characteristic of obesity and thus promoting insulin resistance. Third, a genetic variant with reduced GIPR function is associated with lower OPN and better insulin sensitivity.

OPN is one of the most abundant cytokines in adipose tissue from obese individuals where it specifically is localized in and around inflammatory cells and in adipocytes ([@B3]). We show here that GIP in a dose-dependent fashion in concert with insulin stimulates OPN expression in adipocytes, which in turn could contribute to the inflammation and insulin resistance characteristic of obesity. Importantly, these effects were seen acutely and would therefore be independent of expansion of adipose tissue. Although data in rodents strongly support the view that inhibition of OPN improves insulin sensitivity, data in humans are merely of associative character, where OPN expression in adipose tissue was inversely correlated with measures of total-body insulin sensitivity. In addition, it has been shown that inhibition of OPN by a neutralizing antibody reduced inflammation in adipose tissue and liver in diet-induced obese mice ([@B19]). It may not be feasible to use such antibodies in humans, but our data suggest that similar effects can be achieved by reducing GIP effects in adipose tissue as carriers of the A allele in the *GIPR* variant had lower OPN expression in adipose tissue as well as reduced body weight, which also included reduced abdominal fat. Since GIP stimulates adipose tissue formation independently of its effect on insulin secretion, inactivation of GIPR in adipose tissue has been suggested as a strategy to treat obesity ([@B5]). Our data suggest that it might also improve insulin sensitivity. There was also higher expression of *GIPR* transcript observed in visceral as compared with subcutaneous fat in a group of obese nondiabetic subjects undergoing bariatric surgery. However, we could not exclude the possibility of a confounder effect, as unfortunately, similar samples were not available from the general population, and this could thus be specific to morbidly obese individuals.

As alternative splicing of the *GIPR* results in isoforms with both stimulatory and inhibitory properties in mice ([@B18]), we also studied whether there would be allele-specific effects on splicing that could explain the reduced effect of GIP in adipose tissue. Our data suggest that this could be a possible scenario as carriers of the A allele showed a lower amount of the exon 9--containing isoform, which is required for transmembrane activity. Given the small number of individuals with information on splicing pattern, it would be necessary to obtain not only replication in additional samples but also information on *GIPR* mRNA splicing in different tissues.

In conclusion, we describe a link between GIP and OPN in adipose tissue that could link GIP to insulin resistance ([Fig. 3](#F3){ref-type="fig"}). Exactly what mechanisms mediate this effect are not known; however, our recently published data indicate a role for the transcription factor nuclear factor of activated T cells since the effect of GIP on OPN expression could be inhibited by a blocker of nuclear factor of activated T cells ([@B20]). From a therapeutic point of view, it would be important to characterize different GIPR splice isoforms in different human tissues to obtain information on their activating/inactivating properties.

![Diagram of the design and summary of the study. DEXA, dual-energy X-ray absorptiometry. P-GIP, plasma-GIP.](2088fig3){#F3}
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###### Supplementary Data

This article contains Supplementary Data online at <http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db12-0976/-/DC1>.
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